Journal
BRITISH JOURNAL OF CANCER
Volume 94, Issue 9, Pages 1233-1236Publisher
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6603096
Keywords
epirubicin; docetaxel; metastatic breast cancer; randomised trials; adjuvant anthracyclines
Categories
Ask authors/readers for more resources
The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100mgm(-2) (D) with the combination of docetaxel 80mgm(-2) and epirubicin 75mgm(-2) (ED). The response rate (72 vs 79%), the progression-free survival ( median 9 vs 11 months) and the overall survival ( median 18 vs 21 months) were not significantly different between the ED (n=26) and D arms (n=25), respectively. Leucopaenia, nausea and stomatitis were significantly worse with ED. In conclusion, epirubicin should not be administered in combination with taxanes in metastatic breast cancer patients relapsed after an anthracycline-based adjuvant or neoadjuvant therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available